Pulmatrix Inc (PULM)

PULM under $10

PULM.......................https://stockcharts.com/h-sc/ui?s=PULM&p=W&b=5&g=0&id=p86431144783

PULM............................https://stockcharts.com/h-sc/ui?s=PULM&p=W&b=5&g=0&id=p86431144783

The Pos Scam is heading onto its Target $0.084672 now! I'm glad to have shorted over 100K shares and I'll cover them at $0.084672 because this Upcoming-Bankruptcy Failed drug business will crash to $0.084672 like its NASDAQ peers (KXIN hit $0.1013 from $0.85 while ASTI hit $0.085 from $0.31) did recently.

In order to recover the Huge Losses here, all the existing shareholders should Liquidate PULM at the bids ASAP before it is too late, then use all the cash proceeds to buy its NASDAQ peer or invest in a Hyper-Oversold & Super-Undervalued OTC peer (AFFL) to make Easy & Quick Huge Gain...

Anyway, buying PULM at 52-week-High $2.75 = buying AFFL at $0.4092 which is 10.23 Times of current Super-Ridiculous-Low price $0.04! Which means Easy 10-Bagger Huge & Quick Rally from 52-week-high!

LOL, even buying PULM at current price $1.95 = buying AFFL at $0.2901 which is 8 Times of current Super-Ridiculous-Low price $0.0364! Which means Easy 8-Bagger Huge & Quick Rally from current price!

LOL, even buying PULM at 52-week-low $1.55 = buying AFFL at $0.2306 which is 115.3 Times of current Super-Ridiculous-Low price $0.002! Which means Easy 115-Bagger Huge & Quick Rally from 52-week-low!

So, AFFL is Super Undervalued now v.s. PULM is Super Overvalued currently!

AFFL is at Hyper Oversold status based on its Record-High $6.00 and its recent high $0.089 v.s. PULM is at Hyper Overbought status!

$PULM - Very interesting juncture here.... PUR1900 PH2B Results from Cipla coming... PUR3100 Partnership coming... (?)... what else next?

The failed drug business will soon force the company to file the CH11 or even CH7 BANKRUPTCY...

Be preparing the worst case which should cause all the loyal shareholders to lose 100% of their investment here! PULM will first crash to $0.084672 before the end of this year from its historic high (nearly $3,800)...

Very bad news for PULM! It is heading onto another New low $0.084672 now... Sell ASAP before it is too late!

What an epistle
6000 listed stocks and this one is just one of many
Why not invest in some quality companies

Not at all! The OS will be exploded very soon after finishing its On-Going Huge Dilutions!

LOL, PULM is a Repeated-R/S And ENDLESS-Huge-Diluting Pos Scam! Sell it at currently Super-Overvalued dollar land ASAP before it crashes to a New low $0.084672...

Look at the terrible historic chart below!

PULM will soon break down current 52-week-low $1.55 (on 03/19/2024) and crash to $0.084672 directly in order to match the Same crashing performance (i.e. Down 97.06%) with its NASDAQ peer from current 52-week-high $2.88 (on 06/20/2023) before the end of 2024...

So, we all should liquidate this Death-Spiral And BANKRUPTCY-Soon Pos Scam ASAP, then use just measly $724,346.42 or $724K small amount of cash to Buy-Out the Entire Float (Mere 24.55M shares) of its OTC peer at current ridiculous low price $0.0289 in order to recover our Huge Losses from investing in PULM because that peer can Easily And Quickly surge 100-Bagger or more!

PULM new 52 week low

Some saying billions in rev coming,they sold rights in other countries (except USA ) for 15m (if I remember correctly) and 2% of future sales on the product they couldn’t afford to take thru phase 3,smart to not go into debt like other bio pharma imo,better for shareholders and future of company

20,754 watchers,very few twits posting

Yearly record buying vs selling today (including blue trades with buys)

https://www.prnewswire.com/news-releases/pulmatrix-announces-stopping-the-pur1900-phase-2b-study-patient-enrollment-and-closing-the-study-in-agreement-with-partner-cipla-to-preserve-cash-and-facilitate-pursuit-of-strategic-alternatives-302027934.html

https://www.pulmatrix.com/pipeline.html

relative buying vol up 300%,ask thin to 2.24,moving extremely freely,gross profit 75%,cash 5.89 share,book 5.44

Low float biotech...with enough cash into 2026 sounds good?.....

Will PULM crash to $0.4588 to match the Same crashing Performance (Down 97.06%) with its NASDAQ-Up-Listing-Soon Bio-Medical peer from $15.6 on 12/10/2021 before the end of 2023?

PULM has a New low $1.64 so far!

So, we all should Liquidate this Death-Spiral And BANKRUPTCY-Ready stock (PULM) ASAP, then use just measly $280,000 or $280K small amount of cash to Buy-Out the Entire Float (Mere 2.8B shares) of its peer at current Lowest-Possible Bottom price $0.0001 to recover our Huge Losses from our investing in PULM because the peer can Easily And Quickly surge 34-Bagger again!

CH11 or even CH7 Bankruptcy will be filed with this Huge Fraud Pos Scam in the coming weeks/months...

Please note the Huge Death-Spiral with PULM for nearly Three Years!!!

What kinds of Behind-The-Scene Super-Dark Facts drove the price down to $1.76 so far from over $60 Within only Less Than Three Years or from $20.8 Within just Less Than Two Years?

Anyway its Cannabis-medical peer (SUTI) could Easily surge 34-Bagger to its recent high $0.0034 from its Bottom $0.0001!

So, we all should Liquidate all our PULM shares ASAP, then use all the cash proceeds to buy SUTI at Giant Discount & the Lowest-Possible Bottom price $0.0001 ~ Huge Discount & Very-Ridiculous-Low 52-Week-Low $0.0003 now in order to recover our Huge Losses here!

LOL, only Measly $283,608 Small amount of cash could Buy-Out the ENTIRE Float of SUTI at its current Hyper-Ridiculous-Low asking price $0.0001!

Note, SUTI did Easily surge 34-Bagger to $0.0034 from the Same Bottom $0.0001!

is this SUTI your own sh** ? What the * you are doing ? Spaming with your stinky sh** ? AH

Any idea why the Huge Death-Spiral with PULM for nearly Three Years?

What kinds of Behind-The-Scene Super-Dark Facts drove the price down to $1.76 so far from over $60 Within only Less Than Three Years?

Will this company will file the CH11 or even CH7 Bankruptcy before the end of this year?

Anyway its medical peer (SUTI) could Easily surge 34-Bagger to its recent high $0.0034 from its Bottom $0.0001! So, I would Liquidate all my PULM shares, then use all the cash proceeds to buy SUTI at Giant Discount & the Lowest-Possible Bottom price $0.0001 ~ Huge Discount & Very-Ridiculous-Low 52-Week-Low $0.0003 now in order to recover my Huge Losses here!

LOL, only Measly $283,608 Small amount of cash could Buy-Out the Entire float of SUTI at its current Hyper-Ridiculous-Low asking price $0.0001!

What kinds of Behind-The-Scene Dark Facts drove the price down to $1.76 so far from its recent high $20.8 Within only Less Than Two Years? Why some very stupid Analyst gave PULM a Ridiculous-High Target price $10 most recently? Could the Analyst be the Real Endless seller here?

My reasonable guess is, this company will file the CH11/CH7 Bankruptcy very soon...

Anyway its medical peer (SUTI) could Easily surge to its recent high $0.0034 from its Bottom $0.0001! Could PULM do the Same percentage of Huge rally?

Will the company file the CH11 or even CH7 Bankruptcy very soon?

It is also possible to see PULM crash the Same percentage 97.06% to a New low $0.6118 from its recent high $20.8 on 10/28/2021 like its medical peer (SUTI) did --- from its recent high $0.0034 on 10/05/2021 to its Bottom $0.0001 on 12/02/2022!

Why the ENDLESS price crashes here --- from $15.6 on 12/10/2021 to $1.76 on 10/24/2023 so far?

WIll PULM crash the Same percentage 97.06% to $0.4588 like its medical peer (SUTI) did --- from its recent high 0.0034 to its Bottom 0.0001?

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
https://finance.yahoo.com/news/pulmatrix-announces-fda-acceptance-ind-130500671.html

Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine
BEDFORD, Mass., Sept. 19, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced the U.S. Food and Drug Administration ("FDA") has accepted the PUR3100 investigational new drug ("IND") application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 (Dihydroergotamine Mesylate Inhalation Powder) in the Acute Treatment of Migraine. The PUR3100 formulation uses Pulmatrix's novel, proprietary dry powder delivery technology, iSPERSE™ to deliver DHE via oral inhalation using a dry powder inhaler.

Dr. Margaret Wasilewski, Chief Medical Officer of Pulmatrix noted, "We are pleased with the PUR3100 IND acceptance and receipt of the study may proceed letter for the Phase 2, proof of concept study. We are looking forward to building on the positive safety and pharmacokinetic data established in our phase 1 study."
Ted Raad, Chief Executive Officer of Pulmatrix, commented, "We believe that PUR3100 has the potential to be differentiated from other approved acute migraine therapies currently available on the market, given the convenience of self-administration and the potential for rapid pain relief and improved DHE tolerability. The completed Phase 1 study demonstrated optimal pharmacokinetics and improved tolerability of PUR3100 compared to IV DHE. We are currently pursuing options to advance PUR3100 into a Phase 2 clinical trial to investigate PUR3100 efficacy, safety, tolerability in treating acute migraine subjects."

About PUR3100
PUR3100 is an orally inhaled formulation of dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine. The Phase 1 PUR3100 trial results were presented at the 65th Annual Meeting of the American Headache society in June 2023. Over 38 million patients suffer from migraine in the United States and there is currently no orally inhaled DHE treatment option for patients.

About iSPERSE™ Technology
Our innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs. iSPERSE can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids via the respiratory system for the treatment of both respiratory and non-respiratory diseases.
About Pulmatrix, Inc.
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases and central nervous system ("CNS") disorders using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for lung diseases, such as allergic bronchopulmonary aspergillosis ("ABPA"), Chronic Obstructive Pulmonary Disease ("COPD") and CNS disorders such as acute migraine. Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
For more on our inhaled product candidates please visit: https://www.pulmatrix.com/pipeline.html.




Pulmatrix is a company that develops innovative inhaled therapies for various diseases using its patented iSPERSE™ technology.

iSPERSE™ stands for intelligent Spray-dried Powders with Engineered Respiratory Syncytial Virus (RSV) Properties, and it is a platform that allows the delivery of small or large molecules to the lungs in a dry powder form.

Pulmatrix claims that iSPERSE™ has several advantages over conventional inhalation technologies, such as higher efficiency, lower dose, better safety, and broader applicability.

Pulmatrix has two products in clinical development:

PUR3100 and PUR1800.

PUR3100 is an orally inhaled formulation of dihydroergotamine (DHE), a drug that is used to treat acute migraine.

Pulmatrix has completed a Phase 1 study of PUR3100 and plans to start a Phase 2 study in mid-2023.

PUR1800 is an orally inhaled formulation of itraconazole, an antifungal drug that is used to treat allergic bronchopulmonary aspergillosis (ABPA), a rare lung disease.

Pulmatrix has initiated a Phase 2b study of PUR1800 and expects to report results in mid-2024.

Pulmatrix is also exploring other applications of its iSPERSE™ technology, such as delivering drugs for central nervous system disorders, infectious diseases, and cancer.

Pulmatrix has partnered with several academic and industry collaborators to advance its research and development.

Pulmatrix announced the submission of an IND application to the FDA for PUR3100 in July 2023 and received a study may proceed letter for a Phase 2 trial in September 2023.

The Phase 2 trial is a multicenter, randomized, double-blind, placebo-controlled, single event study to evaluate the safety, tolerability, and efficacy of PUR3100 in patients with acute migraine.

PUR1800 is an orally inhaled dry powder formulation of itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA), a rare inflammatory lung disease.

August 18th 8-K
Revenues increased $0.5 million to $1.8 million for the three months ended June 30, 2023 compared to $1.3 million for the three months ended June 30, 2022. The increase is related to the Company’s revenues recognized in accordance with the Cipla Agreement for PUR1900 during the period.
Pulmatrix’s total cash and cash equivalents balance as of June 30, 2023 was $25.8 million. The Company anticipates that its cash position, based on operational efficiencies and prioritization of spending, is sufficient to fund its operations into the first quarter of 2025.
https://ih.advfn.com/stock-market/NASDAQ/pulmatrix-PULM/stock-news/91783950/form-8-k-current-report

$PULM - PUR3100 Data-Presentation on Monday, 6/5 at Bio International Convention.

$PULM: Bigggggggggg dip to $3........... added 5k shares here


That was uncalled for.

CMON Nowwwwwwwwwwwwwwwwwww


GO $PULM

Yes, the Analyst's Target price is $30 per share! In fact its recent high was $61!

This Hidden Gem (PULM) will soar the Same 5.2-Bagger to $16.458 very soon as its Bio-Tech peer (PBHG: from $0.0005 to $0.0026) did most recently...

If PULM matches the Same performance with its NASDAQ peer (TBLT: from $1.34 to $9.589) then it will hit $22.6487!

The Analyst's target price is $30 a share v.s. PULM only bounced to $7.5x, LOL! Note, its recent high was over $60!

Hopefully this Hidden Gem will soar 5.2-Bagger as its Bio-Tech peer (PBHG: from 0.0005 to 0.0026) did most recently!

10x++ soon enough

Shorts are hitting it hard. Shares are being loaned out today.

First the shake then the bake, something serios about to happen here…

Weekly Chart looks solid...!

Little shakeout/retest going on here - opened with a gap up, not unexpected hour-in action -- yet the fuse has been lit

$PULM

Especially with some sort of material news / bigger implications...

With only 3.1 million shares in the public float PULM could be a rocket!

You may be right. SI has shrunk to all time lows. The big boys know something is going down

Parralax (4.5billion dollar medical/biotech hedge fund) now owns 27%, as of 6/31 due to recent filing -- potentially through confidential filing acquisition? Some other entity may have taken a large >5% position on 8/5, due to that volume spike.

PUR1800 P1B Data publication soon - which will open doors to IPF/Chronic indications, and re-entrance of JnJ partnerships?

Lots of other *ongoing* catalysts that could hit, such as Oexia, Nocion, other licenses/partnerships.

Think the company is ready and funds are supporting the effort for a big pop, just my opinion.

Jumped 65 cents yesterday; today 259K shares pre market, up .75...

can't find news anywhere on why...

buyout?

breakthrough?

partnership?

iSPERSE is King, Multi+billion dollar company in the making, imo. ??

Pulmatrix 3 Current Pipeline Items :
1) PUR1800 (AECOPD): $2.4B Peak U.S. Rev, JNJ, Kinase Inhibitors + New Indications (IPF, Lung Cancer)
**P1B Results being prepared for data publication on chronic dosing indications - *potential near-term catalyst events*

2) PUR1900 (ABPA): Pulmazole - $1.5B Peak Rev in U.S., 50/50 CIPLA Partnership, Expansion opportunity globally & across indications, 'become new standard of care' through reducing limiting side effects on increased oral Itraconazole usage.
*P2B Starting in '23, FDA Fast Tracked, FDA Type-C Reviewed

3) PUR3100 (Migraine):
$575M
U.S. Market; Applying iSPERSE onto previous
$1B
allergen purchase of MAP004 (failed for safety)
*P1 Trials completing around now; P2 & P3 planned for 2023

And the bonus of royalty streams from FEND (PUR003/006) creating the 'air hygiene' category.

Pipeline can expand quickly with iSPERSE being applied to already in-use/developed standards of care of novelty formulations, yielding improved patient care.

$PULM

$3000 reverse split adjusted

HA~!

Yes, The Analyst's Target price is $30 a share!

Wow, Huge Cash Value --- $20.232 a share!

Wow, Huge Book Value --- $18.878 a share!

Wow, PULM did bounce to $7.5 last week! We should see the Same 5.2-Bagger Huge rally here as its peer (PBHG) did most recently --- from 0.0005 to 0.0026!

100% Wrong Info.! The Analyst's Target price is $30 (=$1.5 x 20) and the most recent highs were $21 and $15.6 respectively!

In fact its recent high was $31.8 which is 6%-Higher than the Analyst's Target price $30!

So PULM is at Hyper Oversold status --- from $31.8 to $4.831!

PULM is also Super Undervalued now based on both Huge Book Value ($18.878) And Huge Cash Value ($20.232)!

It will be very easy for PULM to run the Same 5.2-Bagger Quick rally like its peer (PBHG: from $0.0005 to $0.0026) did most recently to create a New 52-week-high $25.1212 (current one is $23.4)!

Wrong, read stocktwits thread for more info on pricetargets.

the old 5$ is the new 100$
raised to 10$ wich is the new 200$

wich you can find at certainly 5 places now.
If you find 10$ its calculated before split.

There has never been a 5$ pt analyst after split,so.
this is the way it is:)

Yes, the Analyst's Target price is $30 and the most recent highs were $21 and $15.6!

In fact the 52-week-high was $31.8 which is 6%-Higher than the Analyst's Target price $30!

PULM is at Hyper Oversold status!

PUL is also Super Undervalued now based on both Huge Book Value ($18.878) And Huge Cash Value $20.232)!

UNREAL DUMPING